Brokerages Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Target Price at $35.82

Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eleven analysts that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $35.82.

SNDX has been the topic of a number of recent research reports. Citigroup increased their target price on Syndax Pharmaceuticals from $30.00 to $34.00 and gave the stock a "buy" rating in a report on Friday, August 16th. JPMorgan Chase & Co. reduced their price objective on shares of Syndax Pharmaceuticals from $34.00 to $33.00 and set an "overweight" rating for the company in a report on Tuesday, August 6th. HC Wainwright boosted their target price on shares of Syndax Pharmaceuticals from $45.00 to $47.00 and gave the stock a "buy" rating in a research report on Wednesday. Bank of America raised their price target on shares of Syndax Pharmaceuticals from $30.00 to $31.00 and gave the company a "buy" rating in a research report on Thursday, August 15th. Finally, StockNews.com raised shares of Syndax Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday.

Institutional Trading of Syndax Pharmaceuticals

A number of hedge funds have recently bought and sold shares of SNDX. Northwestern Mutual Wealth Management Co. bought a new stake in Syndax Pharmaceuticals in the second quarter worth about $27,000. Values First Advisors Inc. purchased a new stake in shares of Syndax Pharmaceuticals during the 3rd quarter worth approximately $30,000. nVerses Capital LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter worth approximately $33,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in Syndax Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company's stock valued at $58,000 after purchasing an additional 541 shares during the last quarter. Finally, Quarry LP grew its holdings in Syndax Pharmaceuticals by 75.0% during the second quarter. Quarry LP now owns 6,125 shares of the company's stock valued at $126,000 after purchasing an additional 2,625 shares during the period.

Syndax Pharmaceuticals Stock Up 1.3 %

SNDX traded up $0.29 during trading on Friday, hitting $21.81. The company's stock had a trading volume of 907,015 shares, compared to its average volume of 1,064,442. The firm has a market capitalization of $1.86 billion, a P/E ratio of -6.01 and a beta of 0.92. The stock's fifty day moving average price is $19.11 and its 200-day moving average price is $20.33. Syndax Pharmaceuticals has a twelve month low of $13.14 and a twelve month high of $25.34.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last issued its earnings results on Tuesday, November 5th. The company reported ($0.98) EPS for the quarter, beating analysts' consensus estimates of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.16 million. During the same period in the previous year, the firm earned ($0.73) earnings per share. Equities research analysts expect that Syndax Pharmaceuticals will post -3.66 EPS for the current fiscal year.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).